Hereditary Disease Foundation

Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing

Retrieved on: 
Thursday, May 2, 2024
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Other Science, Research, Genetics, Science, Clinical Trials, Finance, Doctor of Philosophy, CNS, SVP, Translational medicine, MIT, Genzyme, Cochlea, Hereditary Disease Foundation, Harvard Medical School, Toxicity, HTT, Therapy, Merck, CLN2, Hospital, Safety, Biomedical Research, Samsung Biologics, CHOP, Samsung C&T Corporation, AAV, Koch Institute, Gene expression, Central nervous system, NHP, Program management, Cell, DSM-IV codes, Patient, Gene, Society, Einstein Medical Center Philadelphia, Annual general meeting, Massachusetts General Hospital, Pharmaceutical industry

Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing.

Key Points: 
  • Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing.
  • These limitations have led to the reliance on high-dose injections that cause off-target toxicity and difficulties in scalable manufacturing.
  • The Company’s management team is composed of experienced and respected leaders in gene therapy and neuroscience.
  • Her address will showcase the Company's progress and the vast potential of its technology to solve unmet needs in CNS gene therapy.

Hereditary Disease Foundation Announces Recipients of Inaugural Transformative Research Award

Retrieved on: 
Wednesday, October 4, 2023
DSM-IV codes, HD, CRISPR, Partnership, Broad Institute, University, Hereditary Disease Foundation, HDF, Therapy, PIAS1, University of California, Irvine Medical Center, Breeding, Gene editing, DRS, MBA, Research, Brain, MIT, AAV, Doctor of Philosophy, Harvard University, Harvard Medical School, Jackson, CAG, Protein, MSH3, Thompson, Transformative research, Mouse, Hospital, Somatic, Massachusetts General Hospital, Gene, Nursing, Medical device, MD

Dr. Davidson’s and Dr. Mouro Pinto’s teams each use cutting-edge methods but take different approaches to advance Huntington’s disease research that, if successful, could lead to truly transformative therapies for Huntington’s disease.

Key Points: 
  • Dr. Davidson’s and Dr. Mouro Pinto’s teams each use cutting-edge methods but take different approaches to advance Huntington’s disease research that, if successful, could lead to truly transformative therapies for Huntington’s disease.
  • The Transformative Research Awards were made possible through a partnership between the Hereditary Disease Foundation and a generous group of anonymous donors.
  • “These new awards are designed to move the most innovative work in Huntington’s disease from concept to practice,” said Meghan Donaldson, CEO of the Hereditary Disease Foundation.
  • “We are funding collaborative research teams who are focused on creating new ways to move toward a disease-modifying treatment and provide transformational new insights to the Huntington’s disease research field.

Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research

Retrieved on: 
Thursday, January 26, 2023
PDUFA, Miller, Tauopathy, University, ALS, Ionis Pharmaceuticals, Neurology, Lewy body dementias, Hope, Pharmacokinetics, Nusinersen, Breakthrough Prize, Huntington's disease, Rain, IONS, Palsy, DRS, Breakthrough Prize in Life Sciences, Washington University School of Medicine, Prescription Drug User Fee Act, Alzheimer's disease, Molecular medicine, Hereditary Disease Foundation, Brain, Oligonucleotide, Patient, University of California, Research, BPS Barbara Wilson Lifetime Achievement Award, Neurodegenerative disease, Pharmaceutical industry, Ionis, Science

CARLSBAD, Calif., Jan. 26, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Chief Scientific Officer C. Frank Bennett, Ph.D., has been named a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research.

Key Points: 
  • CARLSBAD, Calif., Jan. 26, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Chief Scientific Officer C. Frank Bennett, Ph.D., has been named a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research.
  • The prizes will be presented during the Eurotau 2023 conference on April 27, 2023, in Lille, France.
  • Bennett, Cleveland and Miller are being recognized for their work advancing antisense technology for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease and tauopathies.
  • A founding member of Ionis, Dr. Bennett is responsible for continuing to advance Ionis' technology and expand its discovery platform.

Hereditary Disease Foundation Announces 2022 Prize Winners for Leadership in Huntington’s Disease Research

Retrieved on: 
Wednesday, October 19, 2022
Neurodegeneration, Lists of diseases, System, Memory, Movement, Deep learning, Therapy, Family, Neuroscience, Stanford University, Professor, Research, ALS, University, Gladstone Institutes, Physiology, Hereditary Disease Foundation, Genetic disorder, Neuron, Doctor of Philosophy, MD, Mitochondrion, Neurology, CEO, Human, University of California, William Ewart Gladstone, HDF, Optimism, Survival, GLOBE, University of California, San Francisco Fetal Treatment Center, HD, Human Genome Project, Death, Center, Gene, Leadership, Pharmaceutical industry, Medical device, Science

-- Natalia Barbosa, PhD (Stanford) is the winner of the 2022 Nancy S. Wexler Young Investigator Prize for her work that is potentially opeining up new strategies for effective therapeutic interventions for Huntington’s disease.   

Key Points: 
  • New York, Oct. 19, 2022 (GLOBE NEWSWIRE) -- The Hereditary Disease Foundation today announced the winners of its 2022 prizes for leadership in Huntingtons disease research.
  • Dr. Finkbeiner and Dr. Barbosa will be featured speakers at the Hereditary Disease Foundation Virtual Gala on Thursday, November 10, 7pm ET.
  • The Wexler Prize honors the pioneering spirit, relentless dedication, and enduring optimism of Nancy S. Wexler, PhD, President of the Hereditary Disease Foundation.
  • Research to find treatments and cures for Huntingtons disease is giving hope to families around the world who are impacted by this devastating disorder, says Meghan Donaldson, CEO of the Hereditary Disease Foundation.

VectorY to Present Poster on Huntington’s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA

Retrieved on: 
Tuesday, August 23, 2022
Health, Genetics, Other Health, Research, Science, Pharmaceutical, Biotechnology, Amyotrophic lateral sclerosis, Hereditary Disease Foundation, Technology, Research, Neuron, Amsterdam Science Park, Mouse, Poster, CAG, HTT, GMP, Antibody, Astrocyte, Lists of diseases, Therapy, Neurodegeneration, Huntingtin, IPS, AAV, Motor neuron, Vaccine, Vectorial addition chain

Several VecTab candidates were identified that effectively removed huntingtin aggregates from U2OS cells that expressed a CAG-repeat-expanded pathological form of huntingtin.

Key Points: 
  • Several VecTab candidates were identified that effectively removed huntingtin aggregates from U2OS cells that expressed a CAG-repeat-expanded pathological form of huntingtin.
  • Huntingtons Disease is caused by aggregates of polyglutamine-rich HTT protein, which result from CAG repeat expansions of the Huntingtin gene.
  • The poster data shows that the platform is also able to target polyglutamine-rich proteins like HTT, demonstrating the clearance of toxic HTT aggregates.
  • Members of the VectorY team will attend the conference in person and will be available to discuss the poster.

Hereditary Disease Foundation Announces 2021 Prizes Recognizing Leadership in Huntington’s Disease Research

Retrieved on: 
Wednesday, October 27, 2021
Research, University, Human Genome Project, Permeability, Disease, Lists of diseases, Pharmacology, National Institute of Molecular Biology and Biotechnology, ET, Family, Memory, Hereditary Disease Foundation, HDF, Human, University of Milan, Foundation, HD, Neurodegeneration, Brain, B cell, Worcester Polytechnic Institute, University of California, Board, CEO, Movement, Cell, Genetic disorder, Laboratory, GLOBE, Pharmaceutical industry

The awards will be presented at the Hereditary Disease Foundation Pathways to Discovery Virtual Gala on Thursday, November 18, at 7pm, ET.

Key Points: 
  • The awards will be presented at the Hereditary Disease Foundation Pathways to Discovery Virtual Gala on Thursday, November 18, at 7pm, ET.
  • Research to find treatments and cures for Huntingtons disease is bringing hope to families around the world who are impacted by this devastating disorder, says Meghan Donaldson, CEO of the Hereditary Disease Foundation.
  • As a disease caused by a mistake on a single gene, Huntingtons disease serves as an ideal model for understanding other brain disorders.
  • Research organized by the Foundation led to the discovery of the genetic marker for Huntingtons disease in 1983.

Hereditary Disease Foundation Launches Fund in Honor of Biomedical Pioneer and Huntington's Disease Researcher Nancy S. Wexler

Retrieved on: 
Tuesday, August 18, 2020
Huntington's disease, Hereditary Disease Foundation, Nancy Wexler, Wexler, Branches of biology, Clinical medicine, Health, Anne B. Young, Milton Wexler

Dr. Wexler is President of the Hereditary Disease Foundation, which funds innovative research to find treatments and cures for Huntington's disease and impact other brain disorders.

Key Points: 
  • Dr. Wexler is President of the Hereditary Disease Foundation, which funds innovative research to find treatments and cures for Huntington's disease and impact other brain disorders.
  • The Nancy S. Wexler Discovery Fund will encourage research collaborations and the recruitment of young scientists.
  • Each year the fund will award the Nancy S. Wexler Young Investigator Prize to a researcher whose work reflects the highest caliber of excellence, diligence and creative thinking.
  • The Hereditary Disease Foundation especially Dr. Nancy Wexler makes my research possible and is the reason why I joined the ranks of Huntington's disease researchers," he added.

Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize for Innovation in Science

Retrieved on: 
Tuesday, October 23, 2018
Deconstructivism, Architecture, Visual arts, Huntington's disease, Frank Gehry, Organic architecture, Hereditary Disease Foundation, Arts

The Leslie Gehry Brenner Prize for Innovation in Science award is given to a HD researcher who embodies qualities of inventiveness and imagination in science.

Key Points: 
  • The Leslie Gehry Brenner Prize for Innovation in Science award is given to a HD researcher who embodies qualities of inventiveness and imagination in science.
  • The Foundation created the Leslie Gehry Brenner Prize for Innovation in Science to honor the memory of HDF founder Frank Gehry's daughter.
  • "I am honored and grateful to be recognized by the Hereditary Disease Foundation and the Gehry family," said Dr. Bennett.
  • Frank's accomplishments honor the spirit and memory of Leslie Gehry by embodying originality, spontaneity, precision and rigor all critical attributes in a scientist."